Skip to content

Study · Animal study (in vivo) · wistar rat · 2025

3 results

Central administration of p234, kisspeptin antagonist, but not kisspeptin-10, reduces the power of epileptiform activity and slow EEG waves in male rats.

Kalkan ÖF, Şahin Z, Aktaş O, Yildirim A, Aydin Abidin S, Özyaşar AF, Uzun İ, Abidin İ

Neurological research21 Jan 2025Cited by 2 (Europe PMC)

PMID39838653 (opens in a new tab)DOI10.1080/01616412.2025.2456293 (opens in a new tab)PepBankPUB-39838653
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with 4-aminopyridine-induced epileptiform activity, kisspeptin‑10 given 20 minutes after induction did not change the activity (p > 0.05).

    In plain wordsIn rats with induced seizure-like brain activity, kisspeptin‑10 given afterwards did not change that activity compared with the seizure-inducing drug alone.

    Peptide
    Kisspeptin-10
    Outcome
    No significant change4-AP-induced epileptiform activity after post-treatment
    Study

    Wistar ratn: not reported in source

    4-aminopyridine-induced epileptiform activity under ketamine/xylazine anaesthesia
    Comparator
    4-AP alone
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    200 pmol · intracerebroventricularAs given in this study (Wistar rat).

    Source sentences

    Summary
    Neither kisspeptin-10 nor p234 post-treatment affected 4-AP-induced epileptiform activity (p > 0.05).
    1 context sentence
    Summary · context
    Thirty-five male Wistar rats were divided into five groups: sham,4-AP (2.5 mg/kg i.p.), kisspeptin-10 post-treatment (200 pmoli.c.v.), p234 post-treatment (1 nmol i.c.v.), and p234 pre-treatment (1 nmol i.c.v.).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with 4-aminopyridine-induced epileptiform activity, kisspeptin‑10 did not alter the spectral analysis of the EEG bands (p > 0.05).

    In plain wordsIn rats, kisspeptin‑10 did not change the brain-wave frequency bands compared with 4-AP alone.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeEEG band spectral analysis
    Study

    Wistar ratn: not reported in source

    4-aminopyridine-induced epileptiform activity under ketamine/xylazine anaesthesia
    Comparator
    4-AP alone
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    200 pmol · intracerebroventricularAs given in this study (Wistar rat).

    Source sentences

    Summary
    Additionally, kisspeptin-10 did not alter the spectral analysis of the EEG bands or the power of the ECoG (p > 0.05).
    1 context sentence
    Summary · context
    Thirty-five male Wistar rats were divided into five groups: sham,4-AP (2.5 mg/kg i.p.), kisspeptin-10 post-treatment (200 pmoli.c.v.), p234 post-treatment (1 nmol i.c.v.), and p234 pre-treatment (1 nmol i.c.v.).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with 4-aminopyridine-induced epileptiform activity, kisspeptin‑10 did not alter the power of the ECoG (p > 0.05).

    In plain wordsIn rats, kisspeptin‑10 did not change the strength of the brain electrical signal compared with 4-AP alone.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeECoG power
    Study

    Wistar ratn: not reported in source

    4-aminopyridine-induced epileptiform activity under ketamine/xylazine anaesthesia
    Comparator
    4-AP alone
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    200 pmol · intracerebroventricularAs given in this study (Wistar rat).

    Source sentences

    Summary
    Additionally, kisspeptin-10 did not alter the spectral analysis of the EEG bands or the power of the ECoG (p > 0.05).
    1 context sentence
    Summary · context
    Thirty-five male Wistar rats were divided into five groups: sham,4-AP (2.5 mg/kg i.p.), kisspeptin-10 post-treatment (200 pmoli.c.v.), p234 post-treatment (1 nmol i.c.v.), and p234 pre-treatment (1 nmol i.c.v.).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.